Azilsartan Medoxomil (Edarbi) The Eighth Angiotensin II Receptor Blocker
|
|
- Alberta Sutton
- 5 years ago
- Views:
Transcription
1 Medoxomil (Edarbi) The Eighth Angiotensin II Receptor Blocker Jocelyn D. Jones, PharmD, BCPS; Sylvia H. Jackson, PharmD, MEd, CDE; Carmen Agboton, PharmD; and Tonya S. Martin, PharmD, CGP, MAEd INTRODUCTION Hypertension affects approximately one in three adults in the U.S. and is a major risk factor for cardiovascular disease. Each year, hypertension contributes to one of every seven deaths in the U.S. and to nearly half of all cardiovascular disease-related deaths, including stroke. 1 If all hypertensive patients were treated effectively to reach the blood pressure (BP) goals established in current clinical guidelines, 46,000 deaths might be averted each year. 2 In addition to the cost in lives lost, hypertension is costly to the health care system in terms of dollars spent. The American Heart Association recently estimated that the direct and indirect costs of hypertension total more than $93.5 billion per year and that cardiovascular disease and stroke account for 17% of total annual health expenditures in the U.S. 3 Eight classes of medications are currently used in the treatment of hypertension. They include diuretics, angio - tensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta-adrenergic blockers, alphaadrenergic blockers, calcium- channel blockers (CCBs), central alpha-adren - ergic receptor agonists (also called central adrenergic inhibitors), and direct renin inhibitors (DRIs). Until recently, the ARB class consisted of seven agents: candesartan (Atacand, AstraZeneca), epro sartan (Teveten, Abbott), irbesartan (Avapro, Bristol-Myers Squibb/Sanofi), losartan (Cozaar, Merck), olmesartan (Benicar, Daiichi Sankyo), telmisartan (Micardis, Boehringer Ingelheim), and valsartan (Diovan, Novartis). Many of these drugs are available in combination with other antihypertensive agents, such as the DRI aliskiren (Tekturna, Novartis), the CCB amlodipine (Norvasc, Pfizer), and the thiazide diuretic hydro - chlorothiazide (HCTZ). Four ARBs have been approved for indications other than hypertension. Candesartan and valsartan may be used for the treatment of heart failure, 4,5 and irbesartan and losartan are indicated for the treatment of nephropathy in patients with type-2 diabetes and hypertension. 6,7 medoxomil (Edarbi, Ta - keda) is a new addition to the ARB class of antihypertensive agents. It received FDA approval in February INDICATION AND USAGE 5 medoxomil is indicated for the treatment of hypertension in adults 18 years of age and older. It is approved for use alone or in combination with other antihypertensive drugs. CHEMICAL STRUCTURE AND PHYSICAL PROPERTIES 9 Figure 1 shows the chemical structure of azilsartan kamedoxomil, the potassium salt used in the product formulation of azilsartan medoxomil. This salt is practically insoluble in water and is freely soluble in methanol. Each white, round, unscored tablet of azilsartan medoxomil contains mg or mg of the potassium salt, which is equivalent to 40 mg and 80 mg of azilsartan medoxomil, respectively. Dr. Jones is Associate Professor of Pharmacy Practice at Florida A&M University, College of Pharmacy and Pharmaceutical Sciences, Jacksonville, Fla. Dr. Jackson is Assistant Professor of Pharmacy Practice at the university. At the time of this writing, Dr. Agboton was a pharmacy student at the university. She is now a Postgraduate Year 1 at Florida A&M University College of Pharmacy and Pharmaceutical Sciences Apalachee Center. Dr. Martin is Assistant Professor of Pharmacy Practice at Florida A&M University. Drug Forecast is a regular column coordinated by Alan Caspi, PhD, PharmD, MBA, President of Caspi & Associates in New York, N.Y. Disclosure: The authors report no financial or commercial relationships in regard to this article. Figure 1 Chemical structure of azilsartan kamedoxomil, the potassium salt of azilsartan medoxomil P&T October 2011 Vol. 36 No. 10
2 CLINICAL PHARMACOLOGY Mechanism of Action 9 Angiotensin II, a peptide hormone, is the principal pressor agent in the renin angiotensin system (RAS). Angiotensin II is a potent, direct vasoconstrictor. It stimulates the synthesis and release of aldosterone and also promotes renal tubular reabsorption of sodium, resulting in water retention. As an ARB, azilsartan medoxomil selectively inhibits angiotensin II from binding to the angiotensin II type-1 receptor (AT 1 ). This receptor inhibition provides the antihypertensive activity of azilsartan medoxomil because it blocks the pressor effects of angiotensin II. Pharmacodynamics 9 The antihypertensive effects of azilsartan medoxomil are dose-related. This characteristic was observed after an infusion of angiotensin II in healthy subjects. A 32-mg dose of azilsartan medoxomil decreased the maximal pressor effect of angiotensin II by approximately 90% when the drug reached peak plasma concentration. Twenty-four hours after administration, azilsartan medoxomil lowered the pressor effect by approximately 60%. In healthy subjects, single and repeated doses of azilsartan medoxomil increased the plasma concentrations of both angiotensin I and angiotensin II. Renin activity also increased, whereas plasma aldosterone levels decreased. Pharmacokinetics 9 Absorption and Distribution. medoxomil is a prodrug. It is hydrolyzed to the active moiety, azilsartan, in the gastrointestinal (GI) tract during the absorption phase. The estimated absolute bioavailability of azilsartan is 60%. Absorption is not affected by food, and peak plasma concentrations are reached within 1.5 to 3 hours. The apparent volume of distribution of azilsartan medoxomil is 16 L. Similar to other ARBs, the drug is highly bound to plasma proteins (99%). When azilsartan was studied in rats, a minimal amount of radioactivity was found to have crossed the blood brain barrier. In addition, azilsartan crossed the placental barrier and was distributed to the fetus. Metabolism and Elimination. The enzyme principally responsible for the metabolism of azilsartan is cytochrome P450 (CYP) 2C9. is metabolized to two primary metabolites, M-I and M-II, by decarboxylation and O-dealkylation, respectively. These metabolites have low affinity for the AT 1 receptor and therefore have no effect on the pharmacologic activity of azilsartan medoxomil. Renal clearance of this medication is estimated to be 2.3 ml/minute. The elimination half-life is 11 hours, and steadystate concentrations are reached within 5 days. Fifty-five percent of the product is eliminated in the feces, and 42% is excreted in the urine, with 15% of the drug unchanged. PIVOTAL CLINICAL TRIALS The FDA s approval of azilsartan medoxomil was based on the results of seven double-blind, randomized studies involving a total of 5,941 patients with hypertension. 9 The studies ranged from 6 weeks to 6 months in duration, and the doses of azilsartan medoxomil ranged from 20 mg to 80 mg. Pivotal clinical trials of azilsartan medoxomil are described next. White et al. 10 White and colleagues conducted a 6-week, randomized, double-blind, multi - center, placebo-controlled and activecontrolled study to compare the anti - hypertensive effects of the two available doses of azilsartan medoxomil (40 and 80 mg) with that of valsartan (320 mg) and olmesartan medoxomil (40 mg). The study included men and women 18 years of age and older whose clinic systolic BP was between 150 and 180 mm Hg, and whose 24-hour mean systolic BP was between 130 and 180 mm Hg. Patients were excluded from the study if they had secondary hypertension; severe diastolic hypertension; significant renal, metabolic, or psychiatric disorders; unstable cardiovascular disease, or type-1 or poorly controlled type- 2 diabetes mellitus. Night-shift workers, pregnant women, and nursing mothers were also excluded. Eligible patients underwent a 3- to 4- week washout period, which was concurrent with a 2-week, single-blind, pla - cebo-administration period. The patients were then randomly assigned to receive daily doses of azilsartan medoxomil 20 mg, azilsartan medoxomil 40 mg, valsartan 160 mg, olmesartan 20 mg, or placebo. Two weeks later, the doses were doubled in each treatment group, and these higher doses were continued for an additional 4 weeks. A total of 1,291 patients were randomly assigned to the five treatment groups. The patients mean age was 56 years, and 54% were men. The primary efficacy endpoint was the change from baseline in the 24-hour mean systolic BP after 6 weeks of treatment. BP measurements were assessed in the clinic at baseline and at 2, 4, and 6 weeks after randomization. The study also included ambulatory BP monitoring (ABPM). The ABPM recordings were assessed at baseline and at 6 weeks after randomization. Data from 1,088 evaluable patients were analyzed to determine non-inferiority and superiority of the two doses of azilsartan medoxomil compared with valsartan and olmesartan. Table 1 lists the changes in systolic BP observed in each treatment group. The study results showed that azilsartan medoxomil 80 mg was more effective than maximal doses of valsartan and olmesartan in reducing systolic BP without increasing the incidence of adverse events (AEs). Bönner et al. 11 A 24-week, randomized, double-blind study was conducted to compare the antihypertensive efficacy and safety of azilsartan medoxomil with that of the ACE inhibitor ramipril (Altace, Mon - arch). Patients with clinic systolic BPs ranging from 150 to 180 mm Hg were included in the study. The patients were randomly assigned to receive daily doses of azilsartan me - doxomil 20 mg, azilsartan medoxomil 40 mg, or ramipril 10 mg. For the first 2 weeks, the patients received lower initial doses of the study drugs (i.e., azilsartan medoxomil 20 mg and ramipril 2.5 mg). The doses were then maximized in each treatment group for the remainder of the study. A total of 884 men and women were treated. The patients mean age was 57 years, and 52.4% were men. The primary efficacy endpoint was the change in trough sitting clinic systolic BP from baseline. Secondary endpoints included response rates (i.e., clinic systolic BP and diastolic BP below 140/90 mm Hg and/or a reduction of 20/10 mm Hg or Vol. 36 No. 10 October 2011 P&T 635
3 Table 1 Changes From Baseline in 24-hour Ambulatory Systolic Blood Pressure (mm Hg) Baseline 24-hour systolic BP, mean (SE) Change in 24-hour systolic BP (SE) vs. valsartan: Difference P value vs. olmesartan: Difference P value Placebo (n = 134) Medoxomil 40 mg (n = 237) Medoxomil 80 mg (n = 229) Valsartan 320 mg (n = 234) Olmesartan 40 mg (n = 254) (0.9) (0.6) (0.7) (0.6) (0.6) 0.3 ± ± ± ± ± ( 5.1/ 1.3) ( 3.3/0.5) = ( 6.3/ 2.4) < ( 4.4/ 0.6) = BP = blood pressure. CI = confidence interval; SE = standard error of the mean. From White WB, et al. Hypertension 2011;57: With permission from Wolters Kluwer Health. more from baseline) and safety parameters. medoxomil 40 and 80 mg reduced both clinic and mean 24-hour systolic BP significantly more than did ramipril 10 mg (Table 2). Response rates were also significantly greater with azilsartan medoxomil 40 and 80 mg (54.0% and 53.6%, respectively) than with ram - ipril 10 mg (33.8%; P < 0.001). In addition, AEs leading to discontinuation of treatment (2.4% and 3.1% vs. 4.8%) and cough (1.0% and 1.4% vs. 8.2%) were less frequent with both doses of azilsartan compared with ramipril. The investigators concluded that longterm treatment with azilsartan medoxomil was more effective than long-term ramipril in reducing BP and that azil - sartan medoxomil was well tolerated in patients with hypertension. Weber et al. 12 In a double-blind, placebo-controlled study, patients with stage 2 hypertension were randomly assigned to receive azil - sartan medoxomil 40 mg, azilsartan medoxomil 80 mg, or placebo, each given daily in combination with amlodipine 5 mg for 6 weeks. A total of 562 patients were evaluated. The patients mean age was 58 years, and 51% were men. The primary endpoint was the change in 24-hour mean systolic BP, as determined by ABPM. Secondary endpoints included trough sitting clinic systolic BP, ABPM and clinic diastolic BP, response rates, and AEs. Both of the azilsartan-amlodipine combinations significantly lowered 24-hour systolic and diastolic BP compared with placebo plus amlodipine (P < 0.001) (Table 3). Response rates were 43%, 66%, and 69% for placebo plus amlodipine, azilsartan medoxomil 40 mg plus amlodi - pine, and azilsartan medoxomil 80 mg plus amlodipine, respectively. Peripheral edema occurred more often with the placebo combination than with the azilsartan combinations (4.9% vs. 2.1%, respectively). This study demonstrated that the combination of azilsartan medoxomil 40 or 80 mg with amlodipine 5 mg could be efficacious in the treatment of patients with stage 2 hypertension. Moreover, the addition of amlodipine may help to reduce the occurrence of peripheral edema associated with azilsartan medoxomil. Sica et al. 13 Thiazide diuretics are common adjuncts to antihypertensive therapy with ARBs and ACE inhibitors. Most clinical trials involving thiazide diuretic regimens have evaluated the long-acting, thiazide-like diuretic chlorthalidone (Thalitone, Monarch). However, none of the currently available fixed-dose ARB Table 2 Changes From Baseline in Clinic Systolic Blood Pressure (mm Hg) Baseline systolic BP, mean Change in week 24, systolic BP Change vs. ramipril: difference P value Medoxomil 40 mg (n = 294) Medoxomil 80 mg (n = 293) Ramipril 10 mg (n = 292) ± ± ± ± ± ± ( 11.0/ 5.8) < ( 11.7/ 6.4) < BP = blood pressure CI = confidence interval. From Bönner G, et al. J Hypertens. 2010;28(e-Suppl A):e283 (Abstract). With permission from Wolters Kluwer Health. continued on page P&T October 2011 Vol. 36 No. 10
4 continued from page 636 Table 3 Changes in Systolic and Diastolic Blood Pressures (mm Hg) 24-hour mean ABPM, No. patients (%) Baseline systolic BP/ diastolic BP Change Change vs. placebo Clinic, No. patients (%) Baseline systolic BP/diastolic BP Change Change vs. placebo Placebo (n = 185) 166 (90) 153.9/ / (97) 166.1/ / 7.1 combination products contains that diuretic agent. Sica and colleagues therefore conducted a 6-week randomized, double-blind, placebo-controlled trial to evaluate the efficacy of azilsartan medoxomil combined with chlorthalidone in patients with stage 2 hypertension. Individuals were included in the study if they had a clinic systolic BP of 160 to 190 mm Hg and a 24-hour mean systolic BP of 140 to 180 mm Hg. Approximately 450 patients were randomly assigned to receive azilsartan medoxomil 40 mg, azilsartan medoxomil 80 mg, or placebo, each administered with chlorthalidone 25 mg. The primary endpoint was the change from baseline in 24-hour mean systolic BP, as determined by ABPM. Absolute reductions in 24-hour mean systolic BP were greater in the groups given chlorthalidone and azilsartan medoxomil 40 or 80 mg ( 31.7 mm Hg and 31.3 mm Hg, respectively) compared with the group given chlorthalidone and placebo ( 15.9 mm Hg; P < 0.001). Absolute reductions in clinic systolic BP were larger with azilsartan medoxomil 40 or 80 mg plus chlorthalidone 25 mg ( 36.2 or 34.4 mm Hg, respectively) compared with chlorthalidone plus placebo ( 21.8 mm Hg). Amlodipine 5 mg Medoxomil 40 mg (n = 189) 165 (87) 152.6/ / */ 7.5* ( 13.3, 9.1/ 8.8, 6.1) 187 (99) 165.5/ / */ 4.9* ( 13.9, 8.1/ 6.6, 3.2) Medoxomil 80 mg (n = 188) 166 (88) 154.4/ / */ 7.7* ( 13.0, 8.8/ 9.0, 6.3) 183(97) 165.4/ / */ 5.6* 12.5, 6.6/ 7.3, 3.9) ABPM = ambulatory blood pressure monitoring; BP = blood pressure CI = confidence interval. *P < vs. amlodipine + placebo. From Weber MA, et al. J Hypertens 2010;28(e-Suppl A):e279 e280 (Abstract). With permission from Wolters Kluwer Health. This study showed that the addition of chlorthalidone to the available strengths of azilsartan medoxomil could significantly reduce both clinic systolic BP and 24-hour mean systolic BP in patients with stage 2 hypertension. Bakris et al. 14 When combining a thiazide diuretic with an ARB or an ACE inhibitor, manufacturers traditionally use HCTZ despite the research that has been conducted with chlorthalidone combinations and the knowledge that chlorthalidone has a much longer half-life and can lower BP more effectively. 15 Bakris and colleagues conducted a 10-week double-blind, multicenter study of the two thiazide diuretics in combination with azilsartan medoxomil in more than 600 patients with moderate-tosevere hypertension. All of the patients received a daily dose of azilsartan 40 mg for the first 2 weeks of the study. During the following 4 weeks, the patients were randomly assigned to receive fixed-dose combinations of azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg or azilsartan medoxomil 40 mg and HCTZ 12.5 mg. During weeks 7 through 10, the diuretics were titrated to 25 mg in patients who did not reach target BP. Fifteen percent more patients in the HCTZ group required an increase in the diuretic dose compared with the chlor - thalidone group. The primary endpoint was the change in clinic systolic BP from baseline. Ten weeks after the start of the study, the reduction in clinic systolic BP was greater in the group receiving azilsartan medoxomil and chlorthalidone compared with the group given azilsartan medoxomil and HCTZ ( 37.8 mm Hg vs mm Hg, respectively; P < 0.001). The fixed-dose combination of azilsartan medoxomil and chlorthalidone significantly decreased clinic BP measurements and 24-hour mean systolic BP more than azilsartan medoxomil and HCTZ. Conflicting study data have been published regarding the relative efficacy and dose equivalence of the various diuretic agents. No fixed-dose combinations of an ARB and chlorthalidone are currently available in the U.S. A New Drug Application (NDA) has been submitted to the FDA for approval of a fixed-dose product consisting of azilsartan medoxomil and chlorthalidone. 16 The most common AEs (with an incidence of 2% or greater) occurring in hypertensive patients treated with the recommended doses of azilsartan med - oxomil plus chlorthalidone included increased levels of creatinine (11.0%), dizziness (8.2%), increased uric acid levels (3.8%), elevated blood urea nitrogen (2.8%), and fatigue (2.5%). Most creatinine elevations were transient and were generally associated with large reductions in BP. ADVERSE DRUG EFFECTS 9 In clinical trials, 4,814 patients were evaluated for safety during azilsartan medoxomil therapy at daily doses of 20, 40, and 80 mg. A total of 1,704 patients were treated for at least 6 months, including 588 who were treated for at least 1 year. medoxomil was well tolerated, and the incidence of AEs was similar to that of placebo. Rates of withdrawals resulting from AEs were 2.4% for placebo, 2.2% for azilsartan medoxomil 40 mg, and 2.7% for azilsartan medoxomil 80 mg. Hypo - tension and orthostatic hypotension were the most common AEs leading to discontinuation of therapy. Both AEs 638 P&T October 2011 Vol. 36 No. 10
5 occurred in 0.4% of the patients treated with azilsartan medoxomil compared with 0% of the patients receiving placebo. Most of the changes in standard laboratory parameters were not clinically relevant. A small, reversible increase in serum creatinine was observed with patients receiving azilsartan medoxomil 80 mg. This increase may be larger when azilsartan medoxomil is coadministered with chlorthalidone or HCTZ. In addition, serum creatinine levels may be increased in patients with moderate or severe renal impairment or in those who are 75 years of age or older. Diarrhea was the most common AE associated with azilsartan medoxomil, occurring in up to 2% of patients receiving the 80-mg dose in placebo- controlled monotherapy trials, compared with 0.5% of patients who received placebo. Other AEs with a plausible relationship to treatment with azilsartan medoxomil included nausea, asthenia, fatigue, muscle spasm, dizziness, and cough. Low hemo - globin, hematocrit, and red blood cell counts were observed in 0.2%, 0.4%, and 0.3% of patients receiving azilsartan medoxomil, respectively. DRUG INTERACTIONS 9 Because azilsartan medoxomil is metabolized by CYP2C9, caution is advised when azilsartan is administered with strong modulators of this enzyme. Other antihypertensive agents should also be used with caution in combination with azilsartan medoxomil. Nonsteroidal antiinflammatory drugs (NSAIDs), including selective cyclooxygenase-2 (COX-2) inhibitors, may inhibit renal function when administered with ARBs. This effect is reversible and is most likely to occur in elderly, volume-depleted, or renally compromised patients. Renal function should be monitored periodically in these patients when azilsartan medoxomil is used with NSAIDs. CONTRAINDICATIONS 9 There are no clinical contraindications to the use of azilsartan medoxomil. WARNINGS 9 The labeling for azilsartan medoxomil includes a boxed warning regarding the use of this drug in pregnancy. When pregnancy is detected, azilsartan medoxomil should be discontinued as soon as possible. Drugs that act on the RAS, such as azilsartan medoxomil, can cause injury and death to the developing fetus. No clinical studies of azilsartan medoxomil have been conducted in pregnant women. medoxomil is a Pregnancy Category C drug during the first trimester and a Pregnancy Category D drug during the second and third trimesters. It is not known whether this medication is excreted in human milk. Low concentrations of the drug have been found in the milk of lactating rats. The RAS is activated in patients who are volume-depleted or salt-depleted, including patients taking high doses of diuretics. The use of azilsartan medoxomil may result in symptomatic hypo - tension in that population. Volume and salt depletion must be corrected before initiation of azilsartan medoxomil, and treatment should be started with a daily dose of 40 mg. A transient hypotensive episode does not constitute a contraindication to the use of azilsartan medoxomil. The drug may be continued when the patient s BP has been stabilized. Changes in renal function may be anticipated when patients are taking medi - cations that inhibit the RAS. medoxomil, like other ARBs, may cause oliguria or progressive azotemia in volume-depleted patients, in patients with severe congestive heart failure, and in patients with renal stenosis. DOSAGE AND ADMINISTRATION 9 In adults, the recommended dosage of azilsartan medoxomil is 80 mg taken orally once daily with or without food. A starting dose of 40 mg should be considered in patients receiving high doses of diuretics and in volume-depleted and salt-depleted patients. medoxomil may be used with other antihypertensive agents. It has not been studied in patients younger than 18 years of age. Dose adjustments are unnecessary in elderly patients, in those with renal impairment, or in those with mild-to-moderate hepatic dysfunction. The drug s safety and efficacy have not been established in patients with severe hepatic impairment. COST The average wholesale price (AWP) for a month s supply of azilsartan medoxomil 40 or 80 mg is approximately $ P&T COMMITTEE CONSIDERATIONS ARBs are not considered to be first-line agents for the treatment of hypertension. These medications are often used to treat hypertensive patients who are intolerant of ACE inhibitors. In a pivotal clinical study, azilsartan medoxomil 80 mg proved to be significantly more effective at lowering systolic BP than either valsartan 320 mg or olmesartan 40 mg in patients with stage 1 or stage 2 hypertension. 10 The placeboadjusted 24-hour systolic BP was reduced by 14.3 mm Hg compared with reductions of 10.0 mm Hg with valsartan (P < 0.001) and by 11.7 mm Hg with olmesartan (P = 0.009). In addition, as part of a recently published study in which systolic BP was measured over 24 hours in patients with primary hypertension, azilsartan medoxomil 80 mg was significantly more effective at lowering systolic BP compared with valsartan 320 mg ( 15.3 vs mm Hg, respectively; P < 0.001). 18 In another study of patients with primary hypertension, azilsartan medoxomil 80 mg lowered systolic BP by 14.6 mm Hg compared with a reduction of 12.6 mm Hg with olmesartan 40 mg (P = 0.038). 19 A month s supply of the maximum strength of azilsartan medoxomil 80 mg costs less than other currently available ARBs (approximately $90 wholesale vs. $113 to $134, respectively), making it one of the most cost-effective drugs in its class. 17 medoxomil may also become the first ARB to be combined with the potent, long-acting thiazide-like diuretic chlorthalidone. 16 This combination would be an attractive option for patients who require more aggressive lowering of systolic BP. CONCLUSION medoxomil is the eighth ARB to be approved for the treatment of hypertension. Recent studies have demonstrated that azilsartan is more effective than the ARBs olmesartan and valsartan and the ACE inhibitor ramipril at lowering systolic BP. 10,11,18,19 A recent study also Vol. 36 No. 10 October 2011 P&T 639
6 showed that the combination of azilsartan medoxomil and the calcium-channel blocker amlodipine is effective at lowering systolic BP, with a reduced incidence of peripheral edema. 12 Moreover, azilsartan medoxomil, in combination with the thiazide-like diuretic chlorthalidone, was more effective in lowering systolic BP than azilsartan plus HCTZ. 14 Many experts have expressed concern with the implication of azilsartan s superiority, given that the comparison includes chlorthalidone, a diuretic with potency greater than that of HCTZ. Nevertheless, combining an ARB with chlorthalidone may be expected to decrease the pill burden, increase adherence, and provide practitioners with another viable option for treating patients with hypertension. REFERENCES 1. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003;289: Farley TA, Dalal MA, Mostashari F, Frieden TR. Deaths preventable in the U.S. by improvements in use of clinical preventive services. Am J Prev Med 2010; 38: Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: A policy statement from the American Heart Association. Circulation 2011; 123(8): Atacand (candesartan celexetil), prescribing information. Wilmington, Del.: AstraZeneca; April Diovan (valsartan), prescribing information. East Hanover, N.J.: Novartis; April Avapro (irbesartan), prescribing information. New York: Bristol-Myers Squibb Sanofi-Synthelabo Partnership; April Cozaar (losartan potassium), prescribing information). Whitehouse Station, N.J.: Merck & Co., Inc.; July FDA approves Edarbi to treat hyper - tension. February 25, Available at: PressAnnouncements/ ucm htm. Accessed May 4, Edarbi (azilsartan medoxomil), prescribing information. Deerfield, Ill.: Takeda; February White WB, Weber MA, Sica D, et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension 2011; 57(3): Bönner G, Bakris GL, Sica D, et al. Comparison of antihypertensive efficacy of the new angiotensin receptor blocker azilsartan medoxomil with ramipril (Abstract). J Hypertens 2010;28(e-Suppl A): e Weber MA, White WB, Sica D, et al. Antihypertensive efficacy of the novel angio tensin receptor blocker azilsartan medoxomil in combination with amlo - dipine (Abstract). J Hypertens 2010;28 (e-suppl A):e279 e Sica D, Bakris GL, White WB, et al. New angiotensin II receptor blocker azil sartan medoxomil coadministered with chlorthalidone provides potent blood pressure reduction in stage 2 hypertension (Abstract). J Clin Hypertens (Greenwich) 2010; 12(Suppl 1):A Bakris G, White WB, Weber MA, et al. Results of a double-blind randomized study comparing chlorthalidone and hydrochlorothiazide combined with the new angiotensin receptor blocker azilsartan medoxomil in primary hypertension (Abstract LB-OR-03). Presented at the 2010 American Society of Hypertension meeting; May 4, 2010, New York. 15. Dorsch MP, Erickson SR, Bleske BE, Weber AB. Improved nonfatal cardio - vascular events with chlorthalidone compared to hydrochlorothiazide (Abstract OR-8). Presented at the 2010 American Society of Hypertension (ASH) Meeting, May 2, 2010, New York. 16. Takeda submits new drug application in the U.S. for azilsartan medoxomil plus chlorthalidone, an investigational fixeddose combination for the treatment of hypertension, February 24, Available at: html. Accessed August 11, CardinalHealth. Dublin, Ohio. Available at: (pass word-protected). Accessed May 13, Sica D, White WB, Weber MA, et al. Comparison of the novel angiotensin II re ceptor blocker azilsartan medoxomil vs. val sartan by ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich) 2011;13: Bakris GL, Sica D, Weber M, et al. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens (Greenwich) 2011;13: P&T October 2011 Vol. 36 No. 10
PHARMACEUTICAL INFORMATION AZILSARTAN
AZEARLY Tablets Each Tablet Contains Azilsartan 20/40/80 mg PHARMACEUTICAL INFORMATION AZILSARTAN Generic name: Azilsartan Chemical name: 2-Ethoxy-1-{[2'-(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl)-4-biphenylyl]methyl}-
More informationazilsartan medoxomil
azilsartan medoxomil edarbi 40mg Tablet 80mg Tablet ANTIHYPERTENSIVE Angiotensin II Receptor Antagonist FORMULATION: Each tablet contains 40mg Azilsartan medoxomil (as potassium) Each tablet contains 80mg
More informationAmlodipine/olmesartan (Azor ) is indicated for the treatment of hypertension, alone or in combination with other antihypertensive medications.
Page 1 of 8 Policies Repository Policy Title Policy Number Oral Antihypertensive Agents FS.CLIN.9 Application of Pharmacy Policy is determined by benefits and contracts. Benefits may vary based on product
More informationHTN: 80 mg once daily 23,f 80 mg once daily 23,f Hypertension 40, 80 mg $82.66 (80 mg once daily) HTN: 8-32 mg daily in one or two divided doses 1
Detail-Document #260301 This Detail-Document accompanies the related article published in PHARMACIST S LETTER / PRESCRIBER S LETTER March 2010 ~ Volume 26 ~ Number 260301 Comparison of Angiotensin Receptor
More informationAngiotensin II Receptor Blockers Dosage in hypertensive patients as well as patients with left ventricular hypertrophy
Angiotensin II Receptor Blockers [Developed, August 1996; Revised, December 1996; July 1997; June 1998; July 1999; September 2000; July 2001; September 2001; July 2002; July 2003; April 2008; March 2011;
More informationeffects of angiotensin II, a potent vasoconstrictor to cardiovascular and renal disease. Because of the detrimental effects associated
Olmesartan Medoxomil for Hypertension: A Clinical Review Daryl Norwood, PharmD, Evans Branch III, PharmD, Bridget Smith, MD, and Marlon Honeywell, PharmD ABSTRACT Olmesartan medoxomil is the latest angiotensin
More informationAngiotensin II Receptor Antagonists (ARBs), Renin Inhibitors, and Combinations Step Therapy Program Summary
OBJECTIVE The intent of the Angiotensin II Receptor Antagonists (ARBs), Renin Inhibitors, and Combinations Step Therapy (ST) program is to encourage use of cost-effective generic products - ACEIs, ACEI
More informationClass Update: Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Blockers (ARBs), and Direct Renin Inhibitors (DRIs)
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Class Update: Angiotensin-Converting Enzyme Inhibitors
More informationCOMPOSITION. A film coated tablet contains. Active ingredient: irbesartan 75 mg, 150 mg or 300 mg. Rotazar (Film coated tablets) Irbesartan
Rotazar (Film coated tablets) Irbesartan Rotazar 75 mg, 150 mg, 300 mg COMPOSITION A film coated tablet contains Active ingredient: irbesartan 75 mg, 150 mg or 300 mg. Rotazar 75 mg, 150 mg, 300 mg PHARMACOLOGICAL
More informationDon t let the pressure get to you:
Balanced information for better care Don t let the pressure get to you: Current evidence-based goals for treating hypertension A cornerstone of primary care: Lowering high blood pressure prevents cardiovascular
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Antihypertensive Medications Page 1 of 10 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Antihypertensive Medications Prime Therapeutics will review Prior Authorization
More informationAdapted d from Federation of Health Regulatory Colleges of Ontario Template Last Updated September 18, 2017
Insert Logo or Org Name Here Primary Care Medical Directive for Hypertension Management Adapted d from Federation of Health Regulatory Colleges of Ontario Template Last Updated September 18, 2017 Title:
More informationABSTRACT ORIGINAL RESEARCH. Joel Neutel Ali Shojaee Jen-Fue Maa. Adv Ther (2012) 29(6): DOI /s z
Adv Ther (212) 29(6):58 523. DOI 1.17/s12325-12-3-z ORIGINAL RESEARCH Efficacy of Amlodipine/Olmesartan ± Hydrochlorothiazide in Patients Uncontrolled on Prior Calcium Channel Blocker or Angiotensin II
More informationClinical Policy: Angiotesin II Receptor Blockers and Renin Inhibitors Reference Number: CP.HNMC.15 Effective Date: Last Review Date: 08.
Clinical Policy: Reference Number: CP.HNMC.15 Effective Date: 11.16.16 Last Review Date: 08.17 Revision Log Line of Business: Medicaid Medi-Cal See Important Reminder at the end of this policy for important
More informationPRODUCT CIRCULAR. Tablets COZAAR (losartan potassium) I. THERAPEUTIC CLASS II. INDICATIONS III. DOSAGE AND ADMINISTRATION PAK-CZR-T
PRODUCT CIRCULAR Tablets I. THERAPEUTIC CLASS, the first of a new class of agents for the treatment of hypertension, is an angiotensin II receptor (type AT 1 ) antagonist. also provides a reduction in
More informationDaiichi Sankyo s U.S. Products Liability Litigation Settlement Program Moves Forward; More than 97 Percent of Eligible Litigants and Claimants Opt In
Daiichi Sankyo s U.S. Products Liability Litigation Settlement Program Moves Forward; More than 97 Percent of Eligible Litigants and Claimants Opt In Tokyo, Japan and Basking Ridge, NJ June 6, 2018 Daiichi
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Edarbi 20 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 20 mg of azilsartan medoxomil (as potassium).
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Olmesartan/Amlodipine (Azor), Olmesartan/Amlodipine/ HCTZ (Tribenzor) Reference Number: CP.CPA.XX Effective Date: 11.16.16 Last Review Date: 08.18 Line of Business: Commercial See Important
More informationVolume 6; Number 1 January 2012 NICE CLINICAL GUIDELINE 127: HYPERTENSION CLINICAL MANAGEMENT OF PRIMARY HYPERTENSION IN ADULTS (AUGUST 2011)
Volume 6; Number 1 January 2012 NICE CLINICAL GUIDELINE 127: HYPERTENSION CLINICAL MANAGEMENT OF PRIMARY HYPERTENSION IN ADULTS (AUGUST 2011) What s new in hypertension? NICE has issued an updated Clinical
More informationBy Prof. Khaled El-Rabat
What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating
More informationThe P&T Committee Lisinopril (Qbrelis )
Situation Background Assessment The P&T Committee Lisinopril (Qbrelis ) Qbrelis, 1 mg/ml lisinopril oral solution, has recently become an FDA- approved formulation. Current practice at UK Chandler Medical
More informationHypertension Update 2009
Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Diovan, Diovan HCT, Exforge, Exforge HCT, Teveten) Reference Number: CP.HNMC.16 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important
More informationState of the art treatment of hypertension: established and new drugs. Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland
State of the art treatment of hypertension: established and new drugs Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland First line therapies in hypertension ACE inhibitors AT
More informationANGIOTENSIN II RECEPTOR BLOCKERS: MORE THAN THE ALTERNATIVE PRESENTATION BY: PATRICK HO, USC PHARM D. CANDIDATE OF 2017 MENTOR: DR.
ANGIOTENSIN II RECEPTOR BLOCKERS: MORE THAN THE ALTERNATIVE PRESENTATION BY: PATRICK HO, USC PHARM D. CANDIDATE OF 2017 MENTOR: DR. CRAIG STERN, PHARMD, MBA, RPH, FASCP, FASHP, FICA, FLMI, FAMCP RENIN-ANGIOTENSIN
More informationPage 1 of DOSAGE FORMS AND STRENGTHS Tablets: 75 mg, 150 mg, 300 mg (3)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use IRBESARTAN TABLETS safely and effectively. See full prescribing information for IRBESARTAN TABLETS.
More informationManaging Hypertension in Diabetes Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park.
Managing Hypertension in Diabetes 2015 Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park Case Scenario Mike M is a 59 year old man with type 2 diabetes managed
More informationHigh-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension
(2005) 19, 491 496 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE High-dose monotherapy vs low-dose combination therapy of calcium channel blockers
More informationDon t let the pressure get to you:
Balanced information for better care Don t let the pressure get to you: An update on the changing recommendations for treating hypertension New trial data and guidelines have made hypertension care more
More informationHypertension Management: A Moving Target
9:45 :30am Hypertension Management: A Moving Target SPEAKER Karol Watson, MD, PhD, FACC Presenter Disclosure Information The following relationships exist related to this presentation: Karol E. Watson,
More informationAmlodipine plus Lisinopril Tablets AMLOPRES-L
Amlodipine plus Lisinopril Tablets AMLOPRES-L COMPOSITION AMLOPRES-L Each uncoated tablet contains: Amlodipine besylate equivalent to Amlodipine 5 mg and Lisinopril USP equivalent to Lisinopril (anhydrous)
More informationHypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital
Hypertension Update 2008 Warwick Jaffe Interventional Cardiologist Ascot Hospital Definition of Hypertension Continuous variable At some point the risk becomes high enough to justify treatment Treatment
More informationAntihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Antihypertensive Agents Part-2 Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Agents that block production or action of angiotensin Angiotensin-converting
More informationIntroductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs
Introductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs Blood Pressure Normal = sys
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 7 January 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 7 January 2009 LERCAPRESS 10 mg/10 mg, film-coated tablets Pack of 30 (CIP code: 385 953-3) Pack of 90 (CIP code:
More informationHypertension (JNC-8)
Hypertension (JNC-8) Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! The 8 th Joint
More informationII. Angiotensin Receptor Blockers (ARBs) Drug Class Review
DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE DOD BENEFICIARY ADVISORY PANEL I. Uniform Formulary Review Process Under 10 U.S.C. 1074g, as implemented by 32 C.F.R. 199.21,
More informationEfficacy and safety of Olmesartan,Losartan, Valsartan, and Irbesartan in the Control of Essential Hypertension
Efficacy and safety of Olmesartan,Losartan, Valsartan, and Irbesartan in the Control of Essential Hypertension Done by :Meznah zaid Al-mutairi Pharm.D Candidate Princess Nora Bint Abdul Rahman University
More informationConversion of losartan to lisinopril
Cari untuk: Cari Cari Conversion of losartan to lisinopril Dania Alsammarae, Strategy Director and co-founder of Anglo Arabian Healthcare speaks with Neil Halligan of Arabian Business on what it takes
More informationPhase 3 investigation of aprocitentan for resistant hypertension management. Investor Webcast June 2018
Phase 3 investigation of aprocitentan for resistant hypertension management Investor Webcast June 2018 The following information contains certain forward-looking statements, relating to the company s business,
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 27 May 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 27 May 2009 RASILEZ HCT 150 mg/12.5 mg, film-coated tablets B/30 (CIP code: 392 151-6) RASILEZ HCT 150 mg/25 mg, film-coated
More informationByvalson. (nebivolol, valsartan) New Product Slideshow
Byvalson (nebivolol, valsartan) New Product Slideshow Introduction Brand name: Byvalson Generic name: Nebivolol, valsartan Pharmacological class: Beta-blocker + angiotensin II receptor blocker (ARB) Strength
More informationClinical cases with Coversyl 10 mg
Clinical cases Coversyl 10 mg For upgraded benefits in hypertension A Editorial This brochure, Clinical cases Coversyl 10 mg for upgraded benefits in hypertension, illustrates a variety of hypertensive
More informationMetabolism: Azilsartan is a prodrug metabolized by the liver via CYP2C9. Chlorthalidone is metabolized hepatically.
Brand Name: Edarbyclor Generic Name: azilsartan medoxomil and chlorthalidone Manufacturer 1 : Takeda Pharms USA Drug Class 2,3,4,5 : Antihypertensive, Angiotensin II Receptor Blocker; Diuretic, Thiazide
More informationAPROVEL 150 mg/300 mg Sanofi-Aventis
APROVEL 150 mg/300 mg Sanofi-Aventis Composition Aprovel 150 mg tablets: each tablet contains 150 mg irbesartan. Aprovel 300 mg tablets: each tablet contains 300 mg irbesartan. Presentation Tablet: White
More informationScientific conclusions and detailed explanation of the scientific grounds for the differences from the PRAC recommendation
Annex I Scientific conclusions, grounds for variation to the terms of the marketing authorisations and detailed explanation of the scientific grounds for the differences from the PRAC recommendation 1
More informationHypertension Update. Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy
Hypertension Update Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy Introduction 1/3 of US adults have HTN More prevalent in non-hispanic
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationYounger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.
Appendix 2A - Guidance on Management of Hypertension Measurement of blood pressure All adults from 40 years should have blood pressure measured as part of opportunistic cardiovascular risk assessment.
More informationLisinopril 20 converting to losartan
Search Lisinopril 20 converting to losartan Stop wasting your time with unanswered searches. lisinopril 40 mg to losartan conversion,cannot Find low price Best. Winds SSW at 10 to 20. Lisinopril 20 to
More informationAntihypertensive efficacy of olmesartan compared with other antihypertensive drugs
(2002) 16 (Suppl 2), S24 S28 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh compared with other antihypertensive drugs University Clinic Bonn, Department of Internal
More informationLACIPIL QUALITATIVE AND QUANTITATIVE COMPOSITION
LACIPIL lacidipine QUALITATIVE AND QUANTITATIVE COMPOSITION Lacidipine, 2 mg - round shaped white engraved on one face. Lacidipine, 4 mg - oval white with break line on both faces. Lacidipine, 6 mg - oval
More informationHypertension and Cardiovascular Disease
Hypertension and Cardiovascular Disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,
More informationThiazide or Thiazide Like? Choosing Wisely Academic Detailing Conference Digby Pines October 12-14
Thiazide or Thiazide Like? Choosing Wisely Academic Detailing Conference Digby Pines October 12-14 Disclosures Pam McLean-Veysey, Team Leader Drug Evaluation Unit DEU funded by the Drug Evaluation Alliance
More informationAnnual Review of Antihypertensives - Fiscal Year 2009
Annual Review of Antihypertensives - Fiscal Year 2009 Oklahoma HealthCare Authority April 2010 Current Prior Authorization Criteria There are 7 categories of antihypertensive medications currently included
More informationALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic
1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker
More informationAdult Blood Pressure Clinician Guide June 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Blood Pressure Clinician Guide June 2018 Adult Blood Pressure Clinician Guide June 2018 Introduction This Clinician Guide is based on the 2018
More informationClinical Policy: ACEI and ARB Duplicate Therapy Reference Number: CP.PMN.61 Effective Date: Last Review Date: 05.18
Clinical Policy: Reference Number: CP.PMN.61 Effective Date: 08.01.14 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory
More informationAntihypertensive Combinations
This Professional Resource gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER October 2016 ~ Resource #321047 Antihypertensive Combinations
More informationDaiichi Sankyo, Inc. (DSI)
Daiichi Sankyo, Inc. (DSI) Outlook for U.S. Business for 2009 Nov. 7 th, 2007 Joseph P. Pieroni President and CEO Daiichi Sankyo, Inc. Largest Pharmaceutical markets $300 $274.4 Annual Sales (US$ billions)
More informationPhysician/Clinic Collaborative Practice Agreement
Physician/Clinic Collaborative Practice Agreement Effective October 1, 2010, Connecticut Senate Bill 428 (PA 10-117) extends to all settings and medical conditions the opportunity for licensed pharmacists
More informationMICARDIS Composition Pharmacological properties Pharmacokinetics
MICARDIS Boehringer (Tablet) Composition 1 tablet contains 40 or 80 mg [1,1 -biphenyl]-2-carboxylic acid, 4 -[(1,4 dime-thyl- 2 -propyl[2,6-bi-1h-benzimidazole]-1 -yl)methyl] (= telmisartan) Excipients:
More informationIJBCP International Journal of Basic & Clinical Pharmacology. Azilsartan: the novel ARB with unique mechanism of action
Print ISSN: 2319-2003 Online ISSN: 2279-0780 IJBCP International Journal of Basic & Clinical Pharmacology DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20170458 Review Article Azilsartan: the novel ARB
More informationThe Road to Renin System Optimization: Renin Inhibitor
The Road to Renin System Optimization: Renin Inhibitor A New Perspective on the Renin-Angiotensin System (RAS) Yong-Jin Kim, MD Seoul National University Hospital Human and Economic Costs of Hypertension
More informationLOZAR. Composition Each tablet contains Losartan potassium 50 mg.
LOZAR Composition Each tablet contains Losartan potassium 50 mg. Tablets Action Angiotensin II [formed from angiotensin I in a reaction catalyzed by angiotensin converting enzyme (ACE, kininase II)], is
More informationHypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationThe first and only FDA-approved lisinopril oral solution for pediatric patients 6 years of age and older. WARNING: FETAL TOXICITY
MEDICAS DIFFER FROM 5 drug products that are essentially copies of commercially available LIPRIL ORAL AF IMPORAN SAFEY INA WARNING: FEAL OXIC 5 drug products that are essentially copies of commercially
More informationSection 3, Lecture 2
59-291 Section 3, Lecture 2 Diuretics: -increase in Na + excretion (naturesis) Thiazide and Related diuretics -decreased PVR due to decreases muscle contraction -an economical and effective treatment -protect
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationHypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures
Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University
More informationClinical trials and clinical pharmacology 21. Blood Pressure Monitoring 2008, 13:21 27
Clinical trials and clinical pharmacology 21 Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial William B.
More informationCombination therapy Giuseppe M.C. Rosano, MD, PhD, MSc, FESC, FHFA St George s Hospitals NHS Trust University of London
Combination therapy Giuseppe M.C. Rosano, MD, PhD, MSc, FESC, FHFA St George s Hospitals NHS Trust University of London KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email:
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 9 March 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 9 March 2011 TAREG 3 mg/ml oral solution B/1 160 ml (CIP code: 491 474-8) Applicant: NOVARTIS PHARMA SAS valsartan
More informationAntihypertensive Agents
Antihypertensive Agents Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 7, 08, presented by Ezra Levy, Pharm.D! Usual Dose,
More informationWhat in the World is Functional Medicine?
What in the World is Functional Medicine? An Introduction to a Systems Based Approach of Chronic Disease Meneah R Haworth, FNP-C Disclosure v I am a student of the Institute for Functional Medicine. They
More informationInvokana (canagliflozin) NEW INDICATION REVIEW
Invokana (canagliflozin) NEW INDICATION REVIEW Introduction Brand name: Invokana Generic name: Canagliflozin Pharmacological class: Sodium-glucose cotransporter 2 (SGLT2) inhibitor Strength and Formulation:
More information0BCore Safety Profile. Pharmaceutical form(s)/strength: Film-coated tablet 40, 80, 160, 320 mg SE/H/PSUR/0024/003 Date of FAR:
0BCore Safety Profile Active substance: Valsartan Pharmaceutical form(s)/strength: Film-coated tablet 40, 80, 160, 320 mg P-RMS: SE/H/PSUR/0024/003 Date of FAR: 28.02.2013 4.2 Posology and method of administration
More informationIJRPC 2011, 1(3) Patel et al. ISSN: INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACY AND CHEMISTRY
INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACY AND CHEMISTRY Available online at www.ijrpc.com Research Article EVALUATION OF COMPLIANCE AND BLOOD PRESSURE REDUCTION IN PATIENTS TREATED WITH AMLODIPINE
More informationTreating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
More informationManagement of Hypertension
Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal
More informationDifficult to Treat Hypertension
Difficult to Treat Hypertension According to Goldilocks JNC 8 Blood Pressure Goals (2014) BP Goal 60 years old and greater*- systolic < 150 and diastolic < 90. (Grade A)** BP Goal 18-59 years old* diastolic
More informationNeprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary
Neprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1 Indication Entresto Reduce the risk of cardiovascular (sacubitril/valsartan) death
More informationGuidelines for the Prescribing of Sacubitril / Valsartan
Hull & East Riding Prescribing Committee Guidelines for the Prescribing of Sacubitril / Valsartan 1. BACKGROUND Sacubitril valsartan is an angiotensin receptor neprilysin inhibitor, including both a neprilysin
More informationJared Moore, MD, FACP
Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner
More informationLong-Term Care Updates
Long-Term Care Updates July 2015 By Amy Friedman Wilson, PharmD Heart failure (HF) is a clinical condition in which ventricular filling or ejection of blood is structurally or functionally impaired. 1
More informationLOSARTAN + HYDROCHLOROTHIAZIDE HYZAAR /HYZAAR DS
PRODUCT CIRCULAR WPC-HYZ-T-092007 THERAPEUTIC CLASS LOSARTAN + HYDROCHLOROTHIAZIDE HYZAAR /HYZAAR DS Film-Coated Tablet Antihypertensive LOSARTAN + HYDROCHLOROTHIAZIDE (HYZAAR) is the first combination
More informationMICARDIS (telmisartan) tablets, for oral use Initial U.S. Approval: 1998
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use MICARDIS safely and effectively. See full prescribing information for MICARDIS. MICARDIS (telmisartan)
More informationNetwork Hypertension Algorithm
Network Hypertension Algorithm Content Review and Approval: This document is subject to review, revision, and (re)approval by the Clinical Integration and Oversight Committee (CIOC) annually and following
More information8/20/2018. Objectives. What is hypertension? cont. What is hypertension? Epidemiology cont. Epidemiology
Objectives Hypertension (high blood pressure): Clinical Pearls for the Pharmacy Technician Tanya Schmidt PharmD, RPh Director of Central Operations at Thrifty White Pharmacy North Dakota Board of Pharmacy
More information7/7/ CHD/MI LVH and LV dysfunction Dysrrhythmias Stroke PVD Renal insufficiency and failure Retinopathy. Normal <120 Prehypertension
Prevalence of Hypertension Hypertension: Diagnosis and Management T. Villela, M.D. Program Director University of California, San Francisco-San Francisco General Hospital Family and Community Medicine
More informationChapter 23. Media Directory. Cardiovascular Disease (CVD) Hypertension: Classified into Three Categories
Chapter 23 Drugs for Hypertension Slide 37 Slide 41 Media Directory Nifedipine Animation Doxazosin Animation Upper Saddle River, New Jersey 07458 All rights reserved. Cardiovascular Disease (CVD) Includes
More informationDiovan DESCRIPTION. valsartan. Tablets. Rx only. Prescribing Information
T2001-47 89004205 Diovan valsartan Tablets Rx only Prescribing Information USE IN PREGNANCY When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin
More informationIndication as per product monograph: Indicated for the treatment of mild to moderate essential hypertension.
Report on New Patented Drugs Olmetec Under its transparency initiative, the PMPRB publishes the results of the reviews of new patented drug products conducted by Board Staff for purposes of applying the
More informationComposition: Each Tablet contains. Pharmacokinetic properties:
Composition: Each Tablet contains Torsemide 5/10/20/40/100mg Pharmacokinetic properties: Torsemide is well absorbed from the gastrointestinal tract. Peak serum concentrations are achieved within 1 hour
More information4/3/2014 OBJECTIVES BLOOD PRESSURE BASICS. Discuss the new blood pressure guidelines (JNC 8) and recognize the changes from JNC 7
1 OBJECTIVES Discuss the new blood pressure guidelines (JNC 8) and recognize the changes from JNC 7 Review mechanisms for the main drug classes used to treat hypertension Describe the dosing strategies
More informationPreventing and Treating High Blood Pressure
Preventing and Treating High Blood Pressure: Finding the Right Balance of Integrative and Pharmacologic Approaches Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Blood Pressure
More information12.5mg, 25mg, 50mg. 25mg, 50mg. 2.5mg, 5mg, 10mg. 5mg, 10mg, 20mg, 100mg. 25mg. -- $2.81 Acetazolamide (IR, 125mg, 250mg, 500mg (ER)
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Blood Pressure P&T DATE: 5/9/2017 THERAPEUTIC CLASS: Cardiovascular Disorders REVIEW HISTORY: 9/15, 2/13, 2/08, 5/07 LOB
More informationManaging Hypertension in 2016
Managing Hypertension in 2016: Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationClinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital
Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8 Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Objectives Review the Eighth Joint National Committee (JNC
More information